Harrow Health Statistics
Total Valuation
Harrow Health has a market cap or net worth of $635.10 million. The enterprise value is $750.79 million.
| Market Cap | 635.10M |
| Enterprise Value | 750.79M |
Important Dates
The last earnings date was Monday, May 13, 2024, after market close.
| Earnings Date | May 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Harrow Health has 35.38 million shares outstanding. The number of shares has increased by 17.10% in one year.
| Shares Outstanding | 35.38M |
| Shares Change (YoY) | +17.10% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | 14.08% |
| Owned by Institutions (%) | 60.19% |
| Float | 26.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.58 |
| Forward PS | 2.95 |
| PB Ratio | 10.49 |
| P/FCF Ratio | 99.70 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 167.14, with an EV/FCF ratio of 117.86.
| EV / Earnings | n/a |
| EV / Sales | 5.41 |
| EV / EBITDA | 167.14 |
| EV / EBIT | n/a |
| EV / FCF | 117.86 |
Financial Position
The company has a current ratio of 3.01, with a Debt / Equity ratio of 3.16.
| Current Ratio | 3.01 |
| Quick Ratio | 2.51 |
| Debt / Equity | 3.16 |
| Debt / EBITDA | 42.67 |
| Debt / FCF | 30.09 |
| Interest Coverage | -0.38 |
Financial Efficiency
Return on equity (ROE) is -54.60% and return on invested capital (ROIC) is -3.06%.
| Return on Equity (ROE) | -54.60% |
| Return on Assets (ROA) | -11.20% |
| Return on Capital (ROIC) | -3.06% |
| Revenue Per Employee | $440,244 |
| Profits Per Employee | -$99,470 |
| Employee Count | 315 |
| Asset Turnover | 0.50 |
| Inventory Turnover | 4.21 |
Taxes
In the past 12 months, Harrow Health has paid $989,000 in taxes.
| Income Tax | 989,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.83% in the last 52 weeks. The beta is 0.58, so Harrow Health's price volatility has been lower than the market average.
| Beta (1Y) | 0.58 |
| 52-Week Price Change | -4.83% |
| 50-Day Moving Average | 13.07 |
| 200-Day Moving Average | 12.35 |
| Relative Strength Index (RSI) | 73.74 |
| Average Volume (30 Days) | 525,279 |
Short Selling Information
The latest short interest is 4.98 million, so 14.09% of the outstanding shares have been sold short.
| Short Interest | 4.98M |
| Short Previous Month | 5.50M |
| Short % of Shares Out | 14.09% |
| Short % of Float | 18.79% |
| Short Ratio (days to cover) | 8.56 |
Income Statement
In the last 12 months, Harrow Health had revenue of $138.68 million and -$31.33 million in losses. Loss per share was -$0.92.
| Revenue | 138.68M |
| Gross Profit | 96.76M |
| Operating Income | -7.71M |
| Pretax Income | -30.34M |
| Net Income | -31.33M |
| EBITDA | 4.49M |
| EBIT | -8.35M |
| Loss Per Share | -$0.92 |
Balance Sheet
The company has $75.97 million in cash and $191.66 million in debt, giving a net cash position of -$115.69 million or -$3.27 per share.
| Cash & Cash Equivalents | 75.97M |
| Total Debt | 191.66M |
| Net Cash | -115.69M |
| Net Cash Per Share | -$3.27 |
| Equity / Book Value | 60.56M |
| Book Value Per Share | 1.71 |
| Working Capital | 83.71M |
Cash Flow
In the last 12 months, operating cash flow was $7.43 million and capital expenditures -$1.06 million, giving a free cash flow of $6.37 million.
| Operating Cash Flow | 7.43M |
| Capital Expenditures | -1.06M |
| Free Cash Flow | 6.37M |
| FCF Per Share | $0.18 |
Margins
Gross margin is 69.77%, with operating and profit margins of -5.56% and -22.59%.
| Gross Margin | 69.77% |
| Operating Margin | -5.56% |
| Pretax Margin | -21.88% |
| Profit Margin | -22.59% |
| EBITDA Margin | 3.24% |
| EBIT Margin | -6.02% |
| FCF Margin | 4.59% |
Dividends & Yields
Harrow Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.10% |
| Shareholder Yield | -17.10% |
| Earnings Yield | -4.93% |
| FCF Yield | 1.00% |
Analyst Forecast
The average price target for Harrow Health is $29.00, which is 61.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $29.00 |
| Price Target Difference | 61.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 32.26% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on February 8, 2013. It was a reverse split with a ratio of 1:5.
| Last Split Date | Feb 8, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
Harrow Health has an Altman Z-Score of 1.64 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.64 |
| Piotroski F-Score | 3 |